| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6217895 | BAUSCH AND LOMB | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Mar, 2019
(5 years ago) | |
| US6548078 | BAUSCH AND LOMB | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Mar, 2019
(5 years ago) | |
Retisert is owned by Bausch And Lomb.
Retisert contains Fluocinolone Acetonide.
Retisert has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Retisert are:
- US6217895
- US6548078
Retisert was authorised for market use on 08 April, 2005.
Retisert is available in implant;intravitreal dosage forms.
Retisert can be used as treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
The generics of Retisert are possible to be released after 22 March, 2019.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Apr 08, 2012 |
Drugs and Companies using FLUOCINOLONE ACETONIDE ingredient
Market Authorisation Date: 08 April, 2005
Treatment: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye
Dosage: IMPLANT;INTRAVITREAL
RETISERT family patents
